Eric Topol on Nostr: A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 ...
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
https://www.nejm.org/doi/full/10.1056/NEJMoa2410819 
Published at
2024-11-13 22:17:11Event JSON
{
"id": "91c62226f6ad707cfd26500a85a67a96ea76a26758e910b04408d7450078a4d4",
"pubkey": "5077f486a3f2f72d07e0efd5cb00aa243734739327371edd92d5c63a7b7dfe53",
"created_at": 1731536231,
"kind": 1,
"tags": [
[
"imeta",
"url https://media.mstdn.social/media_attachments/files/113/477/958/091/730/973/original/ee722cff5c036004.png",
"m image/png",
"dim 1414x792",
"blurhash U3Ss4~Io00M{?a-;WB-;M{D%9FM{9Fxa-:of"
],
[
"proxy",
"https://mstdn.social/users/erictopol/statuses/113477958461289293",
"activitypub"
]
],
"content": "A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of \u003e2,500 participants with obesity, absolute reduction of 10/100 treated\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2410819\n\nhttps://media.mstdn.social/media_attachments/files/113/477/958/091/730/973/original/ee722cff5c036004.png",
"sig": "1c269113f8069a18c92957c3a1b224188cc51f9bdfdcbbb7f3bcb1b6413af0b742d81252c51740e3d93f20b6cac27a1914059ed1e93f0bfb18a0be2949649c9f"
}
